Drugs / MSC303
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07000292 | Jun 2025 → May 2026 overdue | lupus nephritis, pauci-immune glomerulonephritis with ANCA | Shanghai Changzheng Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSC303 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07000292 ↗ |
| Action | Deplete | “MSC303 recruits activated T cells around B cells, thereby enhancing the killing effect on B cells.” NCT07000292 ↗ |
| Route | Subcutaneous | “Subcutaneous Injection of MSC303” NCT07000292 ↗ |
| Target | CD20 | “targeting both CD20 and CD3” NCT07000292 ↗ |